
-
89bio Inc. NasdaqGM:ETNB 89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. The company was founded in 2018 and is headquartered in San Francisco, California.
Location: 655 Montgomery Street, San Francisco, CA, 94111, United States | Website: https://www.89bio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
830.9M
Cash
638.8M
Avg Qtr Burn
-99.96M
Short % of Float
15.23%
Insider Ownership
0.63%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Pegozafermin (BIO89-100) (FGF21 analog) Details metabolic dysfunction-associated steatohepatitis | Phase 3 Data readout | |
Pegozafermin (BIO89-100) (FGF21 analog) Details Severe hypertriglyceridemia | Phase 3 Data readout | |
Pegozafermin (BIO89-100) (FGF21 analog) Details Non-alcoholic steatohepatitis | Phase 3 Update |